Adam is a Global Practice Lead and Partner at Prescient. A health economist by training, he has 25 years of global pricing and market access experience in consulting and the pharmaceutical industry, including roles at Aventis, GlaxoSmithKline and Baxter Healthcare. He is an expert in healthcare policy relating to pricing, reimbursement, and patient access to medicines for rare diseases and oncology.
Featured
The Living Launch Plan: Keeping Pharma Launch Strategy Aligned
Discover how a living launch plan helps pharmaceutical teams adapt to evolving evidence, competitive dynamics, and changing market conditions.
News and insights
Featured
The New Drivers of Pharma Launch Uptake
Learn why precision in launch strategy is becoming essential for improving pharmaceutical launch uptake and commercial performance.
One-Size-Fits-All Launches Are Over
Read the article to discover why modern pharma launches require a precision approach, helping teams prioritize Must-Win Moments, reduce risk, and improve launch success.
ONWARD: Driving Equitable Access and System Readiness in Cancer Care
This Dolon Institute paper highlights six interconnected barriers affecting timely access to oncology innovation, drawing on examples from healthcare systems around the world.
Careers
Work with us
If you're looking to stretch your thinking, lead with purpose, and be part of a culture that values curiosity, accountability and trust, you're in the right place.
